AstraZeneca
-
AstraZeneca and Forest Laboratories to initiate phase 3 clinical trials for ceftazidime/avibactam
Treatment for serious Gram-negative bacterial infections.
AstraZeneca | 18 October 2011
-
AstraZeneca increases investment in China with new $200 million manufacturing facility
New manufacturing facility will enable AstraZeneca to meet the growing demand for its products in China.
AstraZeneca | 10 October 2011
-
AstraZeneca announces first approval of FASLODEX in Japan
In Japan, it is estimated that annually 10,000 women with metastatic breast cancer will have their cancer recurring or progressing post endocrine therapy.
AstraZeneca | 26 September 2011
-
ONGLYZA maintained reductions in blood sugar levels in adults with type 2 diabetes
Results from 52 weeks in investigational study extension.
AstraZeneca | 16 September 2011
-
AstraZeneca announces top-line results from SATURN study
AstraZeneca has announced top-line results from SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80…
AstraZeneca | 02 September 2011
-
AstraZeneca's NEXIUM receives first regulatory approval in Japan
AstraZeneca announced that NEXIUM (esomeprazole magnesium) 10 mg and 20 mg capsules have received regulatory approval in Japan for the treatment of acid-related conditions including non-erosive reflux disease (NERD), reflux esophagitis, and peptic ul…
AstraZeneca | 01 July 2011
-
AstraZeneca, PTC Therapeutics announce strategic oncology drug discovery collaboration
AstraZeneca and PTC Therapeutics Inc announced that they have entered into an exclusive research collaboration and license agreement. This is for the application of PTC’s proprietary GEMS technology (Gene Expression Modulation by Small-molecules) f…
AstraZeneca | 30 June 2011
-
BMS, AstraZeneca announce results from extended study of type 2 diabetes treatment
•Extension of study evaluated safety and efficacy of dapagliflozin plus metformin versus placebo plus metformin at 102 weeks.
AstraZeneca | 27 June 2011
-
AstraZeneca, Heptares to investigate important GPCR drug targets
AstraZeneca and Heptares Therapeutics announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). GPCRs are among the largest and most imp…
AstraZeneca | 31 May 2011
-
AstraZeneca signs agreement in Japan with Daiichi Sankyo
AstraZeneca announced a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis. AstraZeneca and Daiichi Sankyo will co-promote denosumab after it is approved for use in J…
AstraZeneca | 24 May 2011
